Panacea Biotec · NSE: PANACEABIO · BSE: 531349
Q2 FY24 results · Jul–Sep 2023
Panacea Biotec reported revenue from operations of ₹143.02 crore (up 36.1% from Q2 FY23) and net loss of ₹8.29 crore for Q2 FY24 (Jul–Sep 2023), on a consolidated basis.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 143.02 | 105.12 | +36.1% | 129.19 | +10.7% |
| Other income | 3.23 | 10.45 | −69.1% | 6.08 | −46.9% |
| Total income | 146.25 | 115.57 | +26.5% | 135.27 | +8.1% |
| Profit before tax | (7.78) | 23.31 | Turned loss | 13.03 | Turned loss |
| Net profit for the period | (8.29) | 15.70 | Turned loss | 10.98 | Turned loss |
| EPS, basic (₹) | (1.35) | 2.56 | Turned loss | 1.79 | Turned loss |
| Net margin (%) | -5.8 | 14.9 | 8.5 |
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 94.59 | 48.74 | +94.1% | 89.41 | +5.8% |
| Other income | 2.13 | 7.92 | −73.1% | 3.34 | −36.2% |
| Total income | 96.72 | 56.66 | +70.7% | 92.75 | +4.3% |
| Profit before tax | 3.20 | (6.85) | Turned profit | 1.29 | +148.1% |
| Net profit for the period | 3.20 | (6.85) | Turned profit | 1.29 | +148.1% |
| EPS, basic (₹) | 0.52 | (1.12) | Turned profit | 0.21 | +147.6% |
| Net margin (%) | 3.4 | -14.1 | 1.4 |
Consolidated
- Filed with BSE
- 23 Nov 2023, 15:39 IST
- Board meeting
- 10 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 23 Nov 2023, 15:39 IST
- Board meeting
- 10 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE